Know Cancer

or
forgot password

The Evaluation About the Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids


N/A
16 Years
90 Years
Not Enrolling
Both
Liver Cancer

Thank you

Trial Information

The Evaluation About the Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids


This study might demonstrate a tendency of the improvement in the cumulative tumor
recurrence rate after hepatectomy for liver neoplasm in the Livact group compared to that in
the Control Group. The investigators believe that BCAA seems to be a remarkable benefit for
liver resection, especially on its reduction in the recurrence of liver cancer. This
treatment regimen has potential to offer benefits for clinical use selectively, especially
for patients with chronic liver diseases.


Inclusion Criteria:



- These patients were scheduled for elective liver resection to treat hepatocellular
carcinoma or adenocarcinoma of the liver.

Exclusion Criteria:

- a body-weight loss greater than 10% during the 6 months prior to surgery,

- the presence of distant metastases, or

- serious impairment of organ function due to respiratory, renal, or heart disease.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

Postoperative tumor recurrence rate

Outcome Time Frame:

5 years follow up

Safety Issue:

Yes

Principal Investigator

Takehiro Okabayashi, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Kochi Medical School

Authority:

Japan: Ministry of Education, Culture, Sports, Science and Technology

Study ID:

LIVACT 0801

NCT ID:

NCT01434524

Start Date:

April 2007

Completion Date:

June 2011

Related Keywords:

  • Liver Cancer
  • Cell Transformation, Neoplastic
  • Liver Neoplasms

Name

Location